Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors

Clinical Features Clinical Trial

Official title:

Single-center Real World Prospective Observational Study of Clinical Features, Treatment Patterns, and Survival of Bone and Soft Tissue Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05468970
• Other study ID #: ZZUSC-12
• Status: Recruiting
• Start date: August 3, 2022
• Est. completion date: July 31, 2032

Study information

• Verified date: August 2023
• Source: Henan Cancer Hospital
• Contact: Wang Jiaqiang, Dr.
• Phone: 13592413731
• Email: wjqwtj[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor.

Description:

It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor. This study is a single-center, prospective, real-world observational study that plans to enroll all eligible patients. Basic information, treatment methods, and prognostic information of these patients were collected.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 6000
• Est. completion date: July 31, 2032
• Est. primary completion date: July 31, 2032
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 99 Years

Eligibility

Inclusion Criteria:

All ages, male and female.

The pathological diagnosis of BSTS in our hospital was a subtype.

Has received at least one hospitalization in this hospital.

The target lesions could be evaluated according to the efficacy evaluation criteria of solid tumor (RECIST; Version 1.1) Measure diameter changes.

Exclusion Criteria:

No definite pathology.

Related Conditions & MeSH terms

• Bone and Soft Tissue Tumors
• Clinical Features
• Soft Tissue Neoplasms

Intervention

Other:
• NO Intervention
NO Intervention

Locations

Country	Name	City	State
China	Department of Bone and Soft Tissue ,Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Pathologically confirmed events leading to death	Up to approximately 120months
Primary	6/5000 Progression-free survival	The time from the first use of the treatment to the observation of disease progression	Up to approximately 48months